Merck: FDA Approves New Monotherapy Indication for Keytruda
July 31 2019 - 7:26AM
Dow Jones News
By Colin Kellaher
Merck & Co. (MRK) on Wednesday said the U.S. Food and Drug
Administration approved a new monotherapy indication for its cancer
drug Keytruda in a form of esophageal cancer.
The Kenilworth, N.J., drug maker said the approval covers
patients with recurrent locally advanced or metastatic squamous
cell carcinoma of the esophagus whose tumors express PD-L1
(combined positive score >=10) as determined by an FDA-approved
test, with disease progression after one or more prior lines of
systemic therapy.
Keytruda, a cancer drug that harnesses a patient's immune system
to fight tumors, has previously been approved in indications in
lung, skin, bladder and other cancers.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
July 31, 2019 07:11 ET (11:11 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2023 to Apr 2024
